Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8041 to 8055 of 8973 results

  1. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  2. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued Reference number: GID-TA10134

    Technology appraisal guidance
    Discontinued

  3. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued Reference number: GID-TA10221

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495]

    Discontinued Reference number: GID-TA10395

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued Reference number: GID-TA10418

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    Discontinued Reference number: GID-TA10906

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development Reference number: GID-TA10747 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  10. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  11. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued Reference number: GID-TA10154

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  13. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

    Technology appraisal guidance
    Discontinued

  15. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development